Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating on the stock.

VYGR has been the topic of a number of other reports. Wedbush initiated coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, Citigroup initiated coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $17.43.

Voyager Therapeutics Stock Down 2.3 %

Shares of VYGR traded down $0.13 during mid-day trading on Friday, hitting $5.60. The stock had a trading volume of 81,802 shares, compared to its average volume of 316,990. Voyager Therapeutics has a fifty-two week low of $5.19 and a fifty-two week high of $10.66. The company’s fifty day simple moving average is $6.15 and its two-hundred day simple moving average is $6.84. The company has a market cap of $305.91 million, a PE ratio of 7.89 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the business posted ($0.59) EPS. Equities analysts expect that Voyager Therapeutics will post -0.89 earnings per share for the current year.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.53% of the stock is currently owned by company insiders.

Institutional Trading of Voyager Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Great Point Partners LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter worth about $12,668,000. FMR LLC increased its stake in Voyager Therapeutics by 26.9% in the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after buying an additional 19,622 shares during the period. Armistice Capital LLC lifted its position in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after buying an additional 6,740 shares during the period. Finally, Barclays PLC grew its holdings in shares of Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after acquiring an additional 37,398 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.